May 2, 2018 — Conavi Medical Inc. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Novasight Hybrid System. The system enables simultaneous imaging of coronary arteries with both intravascular ultrasound (IVUS) and optical coherence tomography (OCT). IVUS or OCT are typically used by interventional cardiologists to image coronary anatomy during angioplasty and stenting procedures.
The Novasight Hybrid System offers the capability to acquire both IVUS and OCT images using a single catheter. This provides the resolution and contrast of OCT with the larger field of view of IVUS, and displays the images in a precisely co-registered fashion, according to Brian Courtney, M.D., president and CEO of Conavi.
For more information: www.conavi.com